Real-world data from nearly 1.5 million administrations of intranasal esketamine (Spravato) show that its safety profile—including risks of sedation, blood pressure changes, and dissociation—remains consistent with clinical trial findings.
Gerard Sanacora, M.D., Ph.D.
Advertisement
Articles by Gerard Sanacora, M.D., Ph.D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Anitocabtagene Autoleucel Demonstrates Deep, Durable Responses and Improved MRD-Negativity in RRMM
2
Inclisiran, PCSK9s Elicits Sustained LDL-C Reductions in Familial Hypercholestrolemia
3
Delayed Statin Initiation Following Detection of High LDL-C Raises Risk of Heart Attack
4
Biolinq Shine Receives FDA De Novo Classification as First Multi-Analyte Wearable for Type 2 Diabetes
5
